List of Sesquient drug patents

Sesquient is owned by Lupin.

Sesquient contains Fosphenytoin Sodium.

Sesquient has a total of 5 drug patents out of which 0 drug patents have expired.

Sesquient was authorised for market use on 05 November, 2020.

Sesquient is available in solution;intravenous dosage forms.

The generics of Sesquient are possible to be released after 27 February, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9750822 LUPIN Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(6 years from now)

US7635773 LUPIN Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(6 years from now)

US8410077 LUPIN Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(6 years from now)

US9200088 LUPIN Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(6 years from now)

US9493582 LUPIN Alkylated cyclodextrin compositions and processes for preparing and using the same
Feb, 2033

(10 years from now)

Drugs and Companies using FOSPHENYTOIN SODIUM ingredient

Market Authorisation Date: 05 November, 2020

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

SESQUIENT family patents

14

United States

8

Japan

5

China

4

Korea, Republic of

3

Australia

3

Canada

3

Mexico

3

European Union

2

Hong Kong

2

Israel

2

Russia

1

Brazil

1

New Zealand

1

EA

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in